Health Benefits and Pharmacological Aspects of Chrysoeriol

• Published in: Pharmaceuticals (Basel, Switzerland) Vol. 15; no. 8; p. 973
• Main Authors: Aboulaghras, Sara, Sahib, Nargis, Bakrim, Saad, Benali, Taoufiq, Charfi, Saoulajan, Guaouguaou, Fatima-Ezzahrae, Omari, Nasreddine El, Gallo, Monica, Montesano, Domenico, Zengin, Gokhan, Taghzouti, Khalid, Bouyahya, Abdelhakim
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01.08.2022; MDPI
• Subjects: Antioxidants; Bioflavonoids; biological activities; Cancer; Chemical properties; Chromatography; chrysoeriol; Diabetes; Flavones; Flavonoids; Identification and classification; Mass spectrometry; pharmacodynamic; pharmacokinetic; Pharmacokinetics; Pharmacology; Phytochemicals; Review; Scientific imaging; Testing; Morocco; Africa
• ISSN: 1424-8247; 1424-8247
• DOI: 10.3390/ph15080973

A flavone, chrysoeriol is synthetized in several plant species. It comes from several natural sources, especially medicinal plants. The identification and isolation of this compound has been carried out and verified by several research teams using different spectral methods. It seems that the concentration of this molecule is variable and fluctuating depending on the source, the part extracted, the region, and the methods of extraction and characterization. The aim of this paper is to highlight the in vitro and in vivo pharmacological properties of chrysoeriol and to provide insight into its pharmacokinetics. Anticancer, anti-inflammatory, antibacterial, antifungal, anti-osteoporosis, anti-insecticide, and neuroprotective actions have been shown in a number of studies on this chemical. Different mechanisms in theses pharmacological effects include subcellular, cellular, and molecular targets. In vivo pharmacokinetic analysis has proved the good stability of this molecule, showing its promising potential to prevent or treat diseases including cancer, diabetes, inflammation, osteoporosis, Parkinson’s disease, and cardiovascular diseases.